 "private equity, savings")
Apex Laboratories is planning to have some of its 21 intellectual property rights (IPR) related projects handled through a seperate entity, as part of its plans to expand presence to the regulated markets of US and European Union.
The company might also look at diluting a significant minority share in the new entity to Private Equity investors to raise funds to support this plan. The company is expected to reach a turnover of around Rs 750 crore by March, 2021, as against around Rs 500 crore now.
The IP projects which it would move to the new entitiy would be mostly for
